Skip to main content
. Author manuscript; available in PMC: 2023 Apr 8.
Published in final edited form as: Anal Chim Acta. 2022 Feb 24;1201:339621. doi: 10.1016/j.aca.2022.339621

Fig. 4.

Fig. 4.

The proposed mechanisms of metformin in the treatment of IRI-resistant cells and results from FASN activity assay. (A) Schematic pharmacological pathways of metformin in IRI-resistant cells. Metformin inhibits FASN by activating AMPK pathway, and the downstream products, including fatty acids and lipids, are decreased. (B) The relative FASN enzymatic activities of IRI-resistant cells in four different treatments. Results represent four replicates in each treatment for FASN enzymatic activity assay. Standard deviations are labeled as error bars in the histogram. (* p < 0.05; ** p < 0.01; *** p < 0.001 from one-way ANOVA).